Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

1.13
-0.0400-3.42%
Volume:432.11K
Turnover:490.39K
Market Cap:14.93M
PE:-1.00
High:1.17
Open:1.17
Low:1.11
Close:1.17
Loading ...

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

PR Newswire
·
18 Mar

BRIEF-Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need

Reuters
·
10 Mar

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
10 Mar

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for Ht-001 to Support Cancer Patients in Need

THOMSON REUTERS
·
10 Mar

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

PR Newswire
·
10 Mar

Hoth Therapeutics Reports HT-001 Cream Efficacy in Case Study

MT Newswires Live
·
06 Mar

Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate

TIPRANKS
·
06 Mar

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

PR Newswire
·
06 Mar

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
05 Mar

BRIEF-Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease

Reuters
·
04 Mar

Hoth Therapeutics Announces Positive Findings on Gdnf's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

THOMSON REUTERS
·
04 Mar

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

PR Newswire
·
04 Mar

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
11 Feb

BRIEF-Hoth Therapeutics Partners With Ontargetx Research And Development

Reuters
·
10 Feb

Hoth Therapeutics announces collaboration with OnTargetx R&D

TIPRANKS
·
10 Feb

Hoth Therapeutics Partners With Ontargetx R&D to Advance Research for Cancer Fighting Ht-Kit Cancer Therapeutic

THOMSON REUTERS
·
10 Feb

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

PR Newswire
·
10 Feb

Corrected-Hoth Therapeutics Shares Down 5% at $1.10 in Extended Trade Following Filing for Stock Offering (Deletes Erroneous Reference to Share Gain)

THOMSON REUTERS
·
08 Feb

BRIEF-Hoth Therapeutics Files For Common Stock Offering Of Up To $5 Million

Reuters
·
08 Feb

Hoth Therapeutics: Files for Common Stock Offering of up to $5 Mln - SEC Filing

THOMSON REUTERS
·
08 Feb